Compare Stocks: ANIP, ADMA, ANVS, and BLTE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$9.70 -1.1%	$9.26	$7.21 ▼ $20.46	$2.17B	0.78	4.27 million shs	2.60 million shs
ANIP ANI Pharmaceuticals	$74.43 -4.5%	$76.08	$69.58 ▼ $97.00	$1.71B	0.45	385,261 shs	433,643 shs
ANVS Annovis Bio	$1.28 +1.2%	$1.62	$1.04 ▼ $5.50	$54.42M	1.24	868,755 shs	1.14 million shs
BLTE Belite Bio	$168.67 -3.8%	$164.49	$68.21 ▼ $200.00	$6.79B	-1.23	193,940 shs	107,121 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	+3.15%	+13.94%	-0.30%	+12.76%	-38.80%
ANIP ANI Pharmaceuticals	-1.19%	+8.04%	+3.40%	-5.81%	-18.78%
ANVS Annovis Bio	+6.75%	+12.44%	-30.11%	-25.37%	-45.24%
BLTE Belite Bio	+1.12%	+3.49%	+8.87%	+16.30%	+145.97%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$9.70 -1.1%	$9.26	$7.21 ▼ $20.46	$2.17B	0.78	4.27 million shs	2.60 million shs
ANIP ANI Pharmaceuticals	$74.43 -4.5%	$76.08	$69.58 ▼ $97.00	$1.71B	0.45	385,261 shs	433,643 shs
ANVS Annovis Bio	$1.28 +1.2%	$1.62	$1.04 ▼ $5.50	$54.42M	1.24	868,755 shs	1.14 million shs
BLTE Belite Bio	$168.67 -3.8%	$164.49	$68.21 ▼ $200.00	$6.79B	-1.23	193,940 shs	107,121 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	+3.15%	+13.94%	-0.30%	+12.76%	-38.80%
ANIP ANI Pharmaceuticals	-1.19%	+8.04%	+3.40%	-5.81%	-18.78%
ANVS Annovis Bio	+6.75%	+12.44%	-30.11%	-25.37%	-45.24%
BLTE Belite Bio	+1.12%	+3.49%	+8.87%	+16.30%	+145.97%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	2.50	Moderate Buy	$18.67	92.44% Upside
ANIP ANI Pharmaceuticals	2.44	Hold	$100.43	34.93% Upside
ANVS Annovis Bio	2.25	Hold	$12.00	841.18% Upside
BLTE Belite Bio	2.64	Moderate Buy	$218.73	29.68% Upside

Current Analyst Ratings Breakdown

Latest ANIP, ADMA, ANVS, and BLTE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	ANIP ANI Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$85.00
9/14/2026	ADMA ADMA Biologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
9/9/2026	BLTE Belite Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$220.00 ➝ $234.00
9/9/2026	BLTE Belite Bio	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold
9/9/2026	ANIP ANI Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$104.00
9/8/2026	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$245.00
9/4/2026	BLTE Belite Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$303.00
9/4/2026	BLTE Belite Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$303.00
9/3/2026	BLTE Belite Bio	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/3/2026	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$214.00 ➝ $245.00
9/2/2026	ADMA ADMA Biologics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold

(Data available from 9/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$512.28M	4.24	$0.67 per share	14.53	$2.01 per share	4.83
ANIP ANI Pharmaceuticals	$883.37M	1.94	$9.37 per share	7.94	$24.03 per share	3.10
ANVS Annovis Bio	N/A	N/A	N/A	N/A	$0.64 per share	N/A
BLTE Belite Bio	N/A	N/A	N/A	N/A	$20.54 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$146.93M	$0.70	13.86	11.41	N/A	32.98%	40.17%	26.97%	11/4/2026 (Estimated)
ANIP ANI Pharmaceuticals	$78.34M	$4.64	16.04	8.65	N/A	11.07%	27.37%	10.47%	11/6/2026 (Estimated)
ANVS Annovis Bio	-$28.85M	-$1.79	N/A	N/A	N/A	N/A	-685.98%	-258.77%	11/11/2026 (Estimated)
BLTE Belite Bio	-$77.61M	-$2.73	N/A	185.35	N/A	N/A	-11.84%	-11.62%	11/9/2026 (Estimated)

Latest ANIP, ADMA, ANVS, and BLTE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	ANVS Annovis Bio	-$0.4533	-$0.40	+$0.0533	-$0.40	N/A	N/A
8/12/2026	Q2 2026	BLTE Belite Bio	-$0.73	-$0.54	+$0.19	-$0.70	N/A	N/A
8/7/2026	Q2 2026	ANIP ANI Pharmaceuticals	$2.04	$2.21	+$0.17	$1.05	$260.13 million	$266.04 million
8/5/2026	Q2 2026	ADMA ADMA Biologics	$0.1633	$0.16	-$0.0033	$0.16	$125.34 million	$124.40 million
6/30/2026	Q2 2026	BLTE Belite Bio	N/A	-$0.54	N/A	-$0.70	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
ANIP ANI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.49	6.97	3.81
ANIP ANI Pharmaceuticals	0.99	2.91	2.41
ANVS Annovis Bio	N/A	3.47	3.47
BLTE Belite Bio	N/A	33.56	33.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
ANIP ANI Pharmaceuticals	76.05%
ANVS Annovis Bio	15.83%
BLTE Belite Bio	0.53%

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.90%
ANIP ANI Pharmaceuticals	8.10%
ANVS Annovis Bio	15.92%
BLTE Belite Bio	13.29%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	647	223.99 million	215.25 million	Optionable
ANIP ANI Pharmaceuticals	970	22.97 million	21.11 million	Optionable
ANVS Annovis Bio	7	42.68 million	35.89 million	Optionable
BLTE Belite Bio	41	40.27 million	34.92 million	Not Optionable

ANIP, ADMA, ANVS, and BLTE Headlines

Recent News About These Companies

Belite Bio, Inc. Sponsored ADR $BLTE Shares Sold by Squarepoint Ops LLC

September 17, 2026 | marketbeat.com

Belite Bio, Inc (BLTE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 14, 2026 | seekingalpha.com

Insider Selling: Belite Bio (NASDAQ:BLTE) CFO Sells $3,528,096.04 in Stock

September 10, 2026 | insidertrades.com

Belite Bio (NASDAQ:BLTE) CFO Hao-Yuan Chuang Sells 17,962 Shares

September 9, 2026 | marketbeat.com

Belite Bio (NASDAQ:BLTE) CEO Yu-Hsin Lin Sells 26,000 Shares of Stock

September 9, 2026 | marketbeat.com

Belite Bio (NASDAQ:BLTE) CFO Sells $9,275,608.12 in Stock

September 9, 2026 | marketbeat.com

Yu-Hsin Lin Sells 74,435 Shares of Belite Bio (NASDAQ:BLTE) Stock

September 9, 2026 | marketbeat.com

Belite Bio On Track For A Potential Blockbuster Launch In 2027

September 9, 2026 | seekingalpha.com

Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross

September 9, 2026 | zacks.com

Belite Bio Submits Japan Application for Stargardt Disease Drug

September 8, 2026 | finance.yahoo.com

Belite Bio Announces NDA Submission In Japan For Tinlarebant Under Sakigake Designation

September 8, 2026 | rttnews.com

Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the ...

September 8, 2026 | markets.businessinsider.com

Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1

September 8, 2026 | globenewswire.com

Canaccord Genuity initiates coverage of Belite Bio, Inc - depositary receipt at buy

September 6, 2026 | msn.com

Belite Bio (NASDAQ:BLTE) Raised to "Strong-Buy" at Canaccord Genuity Group

September 5, 2026 | marketbeat.com

Belite Bio's Tinlarebant Revenue Estimates Have Multiple Drivers of Upside, Mizuho Says

September 4, 2026 | finance.yahoo.com

Why Is Belite Bio Stock Soaring Friday?

September 4, 2026 | benzinga.com

Belite Bio (NASDAQ:BLTE) Shares Up 6.8% - Still a Buy?

September 4, 2026 | marketbeat.com

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Average Rating of "Moderate Buy" by Analysts

September 3, 2026 | marketbeat.com

Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease

September 2, 2026 | marketbeat.com

Belite Bio, Inc (BLTE) Discusses Prelaunch Strategy and Commercial Opportunity for Tinlarebant in Stargardt Disease Type 1 - Slideshow

September 2, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIP, ADMA, ANVS, and BLTE Company Descriptions

ADMA Biologics NASDAQ:ADMA

$9.70 -0.11 (-1.12%)

Closing price 04:00 PM Eastern

Extended Trading

$9.65 -0.05 (-0.52%)

As of 07:54 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ANI Pharmaceuticals NASDAQ:ANIP

$74.43 -3.48 (-4.47%)

Closing price 04:00 PM Eastern

Extended Trading

$74.42 -0.01 (-0.01%)

As of 07:30 PM Eastern

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Annovis Bio NYSE:ANVS

$1.27 +0.02 (+1.19%)

Closing price 03:59 PM Eastern

Extended Trading

$1.32 +0.04 (+3.37%)

As of 07:30 PM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Belite Bio NASDAQ:BLTE

$168.67 -6.68 (-3.81%)

Closing price 04:00 PM Eastern

Extended Trading

$168.16 -0.51 (-0.30%)

As of 07:37 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANIP, ADMA, ANVS, and BLTE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANIP, ADMA, ANVS, and BLTE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANIP, ADMA, ANVS, and BLTE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIP, ADMA, ANVS, and BLTE Company Descriptions

ADMA Biologics NASDAQ:ADMA

ANI Pharmaceuticals NASDAQ:ANIP

Annovis Bio NYSE:ANVS

Belite Bio NASDAQ:BLTE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANIP, ADMA, ANVS, and BLTE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANIP, ADMA, ANVS, and BLTE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANIP, ADMA, ANVS, and BLTE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIP, ADMA, ANVS, and BLTE Company Descriptions

ADMA Biologics NASDAQ:ADMA

ANI Pharmaceuticals NASDAQ:ANIP

Annovis Bio NYSE:ANVS

Belite Bio NASDAQ:BLTE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools